Difference between revisions of "Denintuzumab mafodotin (SGN-CD19A)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Category:Drug index" to "Category:Drugs")
Line 5: Line 5:
 
# '''Abstract:''' Andres Forero-Torres, Craig Moskowitz, Ranjana H. Advani, Bijal D. Shah, Ana Kostic, Tina M. Albertson, Larissa Sandalic, Baiteng Zhao, Michelle A. Fanale. Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). J Clin Oncol 32:5s, 2014 (suppl; abstr 8505) [http://meetinglibrary.asco.org/content/127120-144 link to original abstract]
 
# '''Abstract:''' Andres Forero-Torres, Craig Moskowitz, Ranjana H. Advani, Bijal D. Shah, Ana Kostic, Tina M. Albertson, Larissa Sandalic, Baiteng Zhao, Michelle A. Fanale. Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). J Clin Oncol 32:5s, 2014 (suppl; abstr 8505) [http://meetinglibrary.asco.org/content/127120-144 link to original abstract]
  
[[Category:Drug index]]
+
[[Category:Drugs]]
 
[[Category:Chemotherapy]]
 
[[Category:Chemotherapy]]
 
[[Category:Intravenous medications]]
 
[[Category:Intravenous medications]]

Revision as of 23:08, 13 June 2018

Mechanism of action

Antibody-drug conjugate

Preliminary studies

  1. Abstract: Andres Forero-Torres, Craig Moskowitz, Ranjana H. Advani, Bijal D. Shah, Ana Kostic, Tina M. Albertson, Larissa Sandalic, Baiteng Zhao, Michelle A. Fanale. Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). J Clin Oncol 32:5s, 2014 (suppl; abstr 8505) link to original abstract